Milk without the cow: TurtleTree Labs, world's first company producing milk from cells, secures pre-seed funding

TurtleTree Labs, the Singapore-based company working with biotechnology to create the full nutritional content of milk, today announced today that it has completed its pre-seed funding round.

Co-founded by CEO Fengru Lin, CSO Rabail Toor, and Chief Strategist Max Rye, TurtleTree Labs is the world's first cell-based milk company using technology to create real milk from animal cells, with no animal needed.

TurtleTree's breakthrough is quite significant; it allows for not just the full functionality of dairy milk but will disrupt the existing baby formula industry.

The pre-seed round, led by Lever VC, a venture capital fund specializing in alternative protein investments, includes KBW Ventures and K2 Global.

"What TurtleTree Labs is doing is fascinating, and their technology could be a serious disruptor in the global dairy industry," said Nick Cooney, Founder and Managing Partner at Lever VC. "They are the first company in the world producing real, whole milk from cell cultivation -- which opens the door for safer, healthier and customized dairy products that can be produced with far fewer natural resources."

"KBW Ventures' interest in TurtleTree stems from both the team vision and the company's strategic approach to the future of food using stem cell technology. Having spent time with the founding team in Singapore, we have a lot of confidence in TurtleTree's progress as a biotech company and in the direction they are taking from a business perspective," said Prince Khaled bin Alwaleed bin Talal Al Saud, founder and Chief Executive Officer, KBW Ventures.

TurtleTree has developed a unique proprietary technology that uses mammary cells to produce real, full milk in clean food production facilities. The end product being the same as human breast milk and cow milk and will be sold as a food product.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.